ZA852830B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA852830B
ZA852830B ZA852830A ZA852830A ZA852830B ZA 852830 B ZA852830 B ZA 852830B ZA 852830 A ZA852830 A ZA 852830A ZA 852830 A ZA852830 A ZA 852830A ZA 852830 B ZA852830 B ZA 852830B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA852830A
Other languages
English (en)
Inventor
Brian Albert Callingham
Robert Charles Hider
George Kontoghiorghes
Michael Arthur Stockham
Original Assignee
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Dev filed Critical Nat Res Dev
Publication of ZA852830B publication Critical patent/ZA852830B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Conveying Record Carriers (AREA)
ZA852830A 1984-04-19 1985-04-16 Pharmaceutical compositions ZA852830B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848410289A GB8410289D0 (en) 1984-04-19 1984-04-19 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA852830B true ZA852830B (en) 1986-12-30

Family

ID=10559910

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA852830A ZA852830B (en) 1984-04-19 1985-04-16 Pharmaceutical compositions

Country Status (15)

Country Link
EP (1) EP0159194B1 (da)
JP (1) JPH0794467B2 (da)
AU (1) AU582153B2 (da)
CA (1) CA1286844C (da)
CY (1) CY1575A (da)
DE (1) DE3579730D1 (da)
DK (1) DK160986C (da)
GB (2) GB8410289D0 (da)
HK (1) HK8091A (da)
IE (1) IE58667B1 (da)
IL (1) IL74949A (da)
NZ (1) NZ211788A (da)
PH (1) PH25348A (da)
SG (1) SG92490G (da)
ZA (1) ZA852830B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
CA1283404C (en) * 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
US4908371A (en) * 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
EP0325559B1 (de) * 1988-01-20 1993-12-15 Ciba-Geigy Ag Verfahren zur Herstellung von Komplexverbindungen
JPH03101676A (ja) * 1989-09-14 1991-04-26 Sansho Seiyaku Co Ltd ２―エトキシメチル―５―ヒドロキシ―γ―ピロン及び同化合物を有効成分とするメラニン生成抑制外用剤
WO1991012822A1 (de) * 1990-03-02 1991-09-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Zubereitungen für die mr-diagnostik
EP0833627B1 (en) 1995-06-10 2004-08-18 Vitra Pharmaceuticals Ltd. Iron compounds, compositions, methods of making the same and uses thereof
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
AU2001287850A1 (en) 2000-09-19 2002-04-02 Vitra Pharmaceuticals Limited Iron compositions
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
US9394324B2 (en) 2010-03-23 2016-07-19 Vifor (International) Ag Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
JP5923161B2 (ja) 2011-03-29 2016-05-24 ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ 鉄欠乏症状および鉄欠乏性貧血の治療および予防のための鉄（ｉｉｉ）錯体化合物
WO2012163938A1 (de) 2011-05-31 2012-12-06 Vifor (International) Ag Fe(iii)-2,4-dioxo-1-carbonyl-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
CA2891572A1 (en) 2012-12-21 2014-06-26 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
JP7033546B2 (ja) * 2016-03-31 2022-03-10 シールド ティーエックス （ユーケー） リミテッド 元素鉄からマルトール第二鉄組成物を生成するための方法
US10508094B2 (en) * 2016-03-31 2019-12-17 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ferrous hydroxides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094149B1 (en) * 1982-03-24 1986-09-10 National Research Development Corporation Pharmaceutical compositions containing a complex of iron with n-substituted 3-hydroxypyrid-2-one or -4-one derivatives
GB2117766B (en) * 1982-03-24 1985-08-29 Nat Res Dev Pharmaceutical compositions
EP0107458B1 (en) * 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions

Also Published As

Publication number Publication date
HK8091A (en) 1991-02-01
CA1286844C (en) 1991-07-23
DK160986B (da) 1991-05-13
CY1575A (en) 1991-12-20
DK175585D0 (da) 1985-04-18
AU582153B2 (en) 1989-03-16
DK160986C (da) 1991-11-11
GB8509813D0 (en) 1985-05-22
NZ211788A (en) 1988-06-30
GB2157686B (en) 1987-12-16
DE3579730D1 (de) 1990-10-25
PH25348A (en) 1991-05-13
AU4141385A (en) 1985-10-24
JPH0794467B2 (ja) 1995-10-11
JPS60248696A (ja) 1985-12-09
EP0159194A3 (en) 1986-03-12
IE850992L (en) 1985-10-19
DK175585A (da) 1985-10-20
GB8410289D0 (en) 1984-05-31
IE58667B1 (en) 1993-11-03
IL74949A (en) 1988-05-31
GB2157686A (en) 1985-10-30
EP0159194A2 (en) 1985-10-23
SG92490G (en) 1991-02-14
EP0159194B1 (en) 1990-09-19

Similar Documents

Publication Publication Date Title
GB8508452D0 (en) Pharmaceutical compositions
GB8403359D0 (en) Pharmaceutical compositions
GB8426672D0 (en) Pharmaceutical compositions
GB2165451B (en) Pharmaceutical compositions
EP0163178A3 (en) Pharmaceutical composition
GB8509814D0 (en) Pharmaceutical compositions
ZA852830B (en) Pharmaceutical compositions
GB8403360D0 (en) Pharmaceutical compositions
GB8503513D0 (en) Pharmaceutical compositions
GB8409961D0 (en) Pharmaceutical compositions
GB2153676B (en) Pharmaceutical composition
GB8524054D0 (en) Pharmaceutical compositions
GB8419244D0 (en) Pharmaceutical compositions
GB8432199D0 (en) Pharmaceutical compositions
CY1980A (en) Pharmaceutical compositions
GB8411116D0 (en) Pharmaceutical compositions
GB8424957D0 (en) Pharmaceutical compositions
GB8426151D0 (en) Pharmaceutical compositions
GB8406667D0 (en) Pharmaceutical compositions
GB8403790D0 (en) Pharmaceutical compositions
GB8426375D0 (en) Pharmaceutical compositions
GB8427486D0 (en) Pharmaceutical compositions
GB8402590D0 (en) Pharmaceutical compositions
GB8427877D0 (en) Pharmaceutical compositions
ZA84895B (en) Pharmaceutical compositions